cagrilintide semaglutide combination cagrisema phase 3 results 2024 2025 Novo Nordisk's stock drops despite hitting goal of III trial Novo Nordisk's CagriSema outperforms Ozempic

While the long-term safety and effectiveness of GLP-1RA for other indications like kidney disease and fatty liver still need verification, attention and research investment in GLP-1RAs for obesity and related conditions are keeping increasing, driving further scientific and medical advancements in metabolic diseases

Headaches can occur, especially if you are reducing caloric intake rapidly

Final Thoughts: It is important to note that the benefits and side effects of these medical weight loss treatments may vary from person to person

ATP Activator

These therapies are prescribed only after a thorough medical evaluation and discussion of potential risks, benefits, and alternatives

In 2019 alone, obesity-related medical care costs in the United States were estimated at approximately $173 billion.(2) These widespread health and economic burdens highlight the urgent need for effective obesity management